The significant non-cash gain inflates profitability metrics; traders should focus on clinical development milestones rather than current earnings. Monitor upcoming IND filings for palbociclib and docetaxel candidates in 2026 and potential Hong Kong IPO of the joint venture.
Price Chart
Executive Summary
Oncotelic Therapeutics reported a $249 million net income for FY 2025, driven by a $365.4 million non-cash gain from the revaluation of its investment in joint venture GMP Biotechnology. The company also highlighted clinical progress in its OT-101 and Deciparticle™ nanoparticle programs.
Key Facts
- Reported net income of $249.0 million for FY 2025, compared to a net loss of $4.8 million in FY 2024
- Non-cash gain of $365.4 million from revaluation of investment in GMP Biotechnology Limited
- Recorded $111.6 million deferred income tax provision related to the gain
- Completed Phase 1 trial of OT-101 in combination with IL-2 for advanced solid tumors
- Initiated Phase 2/3 trial for OT-101 in pancreatic cancer
- Advanced six Deciparticle™ nanoparticle candidates, with everolimus formulation in global clinical trial
Financial Impact
Net income increased by $253.8 million year-over-year, primarily from a $365.4 million non-cash gain on joint venture valuation
Risk Factors
- The $365.4 million gain is non-cash and valuation-based, not reflecting product revenue or cash flow
- Deferred tax liability of $111.6 million may impact future cash obligations
- Clinical trial timelines and regulatory approvals remain uncertain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-016981 |
| Document: form8-k.htm | 0001493152-26-016981 |
| Document: 0001493152-26-016981-index-headers.html | 0001493152-26-016981 |
| Document: 0001493152-26-016981-index.html | 0001493152-26-016981 |
| Document: 0001493152-26-016981.txt | 0001493152-26-016981 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 8-K | $0.0200 | awaiting T+60 | — | $0.0200 (−0.00%) |
Oct 13, 2026 14d ago | 8-K | $0.0200 | awaiting T+60 | — | $0.0200 (−0.00%) |
Jul 14, 2026 14w ago | 8-K | $0.0400 $0.0200 | ▼ −50.00% | ▼ −52.79% | $0.0200 (−50.00%) |
Jun 29, 2026 17w ago | 8-K | $0.0400 $0.0245 | ▲ +38.75% | ▲ +42.59% | $0.0200 (+50.00%) |
May 5, 2026 24w ago | 8-K | $0.0400 $0.0400 | · 0.00% | ▼ −2.06% | $0.0200 (−50.00%) |
Apr 16, 2026 27w ago | 8-K | $0.0400 $0.0360 | ▼ −10.00% | ▼ −17.05% | $0.0200 (−50.00%) |
Apr 2, 2026 29w ago | 8-K | $0.0400 $0.0400 | · 0.00% | ▼ −14.16% | $0.0200 (−50.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers